LRMR
Larimar Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.72
+6.89%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.60
From 52W high−54.37%
Volume1.52M
Market cap$282.04M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$2.60
From 52W high
−54.37%
Volume
1.52M
Market cap
$282.04M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
P/E (TTM)
—
RSI (14)
51.0
MomentumView details →
1D Return
+6.89%
YTD Return
−29.66%
SummaryUpdated Jun 1, 2026
Larimar Therapeutics, Inc. (NASDAQ:LRMR) is a clinical-stage biotechnology company founded in 2014 and based in Bala Cynwyd, Pennsylvania. The company specializes in developing innovative treatments for rare diseases using its proprietary cell penetrating peptide technology platform. Since going public in 2014, Larimar has focused its efforts on advancing novel therapeutic approaches for conditions that currently have limited or no treatment options, with its lead program targeting Friedreich's ataxia, a devastating genetic disorder.
Similar companies
Latest newsMore news →
Larimar Therapeutics appointed John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to CEO Carole Ben-Maimon.36d agoDimensional Fund Advisors LP increased its stake in Larimar Therapeutics, Inc. by 143.8% during the first quarter, purchasing an additional 470,968 shares, according to a recent SEC filing.83d ago